Control problems related to tumor angiogenesis

IECON Proceedings (Industrial Electronics Conference)

Volumn , Issue , 2006, Pages 677-681

  Swierniak, Andrzej ^a   D'Onofrio, Alberto ^b   Gandolfi, Alberto ^c  

^a SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c CNR   (Italy)

Author keywords

Anticancer therapy; Biomathematical applications; Nonlinear control; Optimization; Stability

Indexed keywords

ANNUAL CONFERENCE; ANTIANGIOGENIC; ANTICANCER THERAPY; BIOMATHEMATICAL APPLICATIONS; CANCER CHEMOTHERAPIES; CONTROL PROBLEMS; EQUILIBRIUM POINTS; NONLINEAR CONTROL; OPTIMIZ ATION PROBLEMS; OPTIMIZATION; STABILITY; TUMOR ANGIOGENESIS;

CHEMOTHERAPY; INDUSTRIAL ELECTRONICS; TUMORS;

ELECTRONICS INDUSTRY;

EID: 50249189054     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/IECON.2006.347815     Document Type: Conference Paper

References (21)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl. J. Med. 295, 1971, 1182-1186.
2. Folkman J. Antiangiogenesis: new concept for therapy of solid tumors. Ann. Surg., 175, 1972, 409-416.
3. Kerbel R.S. A cancer therapy resistant to resistance, Nature 390, 1997, 335-340
4. Kerbel R.S. Tumor angiogenesis: past, present and near future. Carcinogenesis, 21, 2000, 505-515
5. Folkman J., Klagsburn M. Angiogenic factors, Science, 235, 1987, 442-447
6. Klagsburn M., Soker S. VEGF/VPF: the angiogenesis factor found?, Curr. Biol., 3, 1993, 699-702.
7. Davis S., Yancopoulos G.D. The angiopoietins: Yin and Yang in angiogenesis, Curr. Top. Microbiol. Immunol., 237, 1999, 173-185
8. Folkman J. Angiogenesis inhibitors generated by tumors, Mol. Med., 1, 1995, 120-122.
9. Bischoff J. Approaches to studying cell adhesion and angiogenesis, Trends Cell Biol., 5, 1995, 69-73.
10. Folkman J., Haudenschild C. Angiogenesis in vitro, Nature, 288, 1980, 551-555.
11. Weidner N. Intramural microvessel density as a prognostic factor in cancer, Am. J.Path., 147, 1995, 9-19.
12. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis, Proc. Natl. Acad. Sci USA, 91, 1994, 4082-4085.
13. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy, Brit. J. Radiol., 66, 1993, 181-196.
14. Anderson A.R.A., Chaplain M.A.J., Continuous and discrete mathematical models of tumor induced angiogenesis, Bull. Math. Biol. 60, 1998, 857-864.
15. Hahnfeldt P., Panigraphy D., Folkman J., Hlatky L. Tumor development under angiogenic signaling: A dynamic theory of tumor growth, treatment response and postvascular dormacy, Cancer Res. 59, 1999, 4770-4778.
16. d'Onofrio A., Gandolfi A., Tumour eradication by antiangiogenic therapy analysis and extensions of the model by Hahnfeldt et al (1999). Math. Biosci. 191, 2004, 159-184.
17. Ergun A., Camphausen K., Wein L.M., Optimal scheduling of radiotherapy and angiogenic inhibitors, Bull. Math. Biol. 65, 2003, 407-424.
18. th IEEE CDC and ECC 2005, 2005, 934-939.
19. La Salle J., Lefschetz S., Stability by Liapunov's Direct Method, Academic Press, New York, 1961
20. Pontryagin L. S., Boltyanski V.G., Gamkrelidze R. V., Mishchenko, The Mathematical Theory of Optimal Processes, Mac Millan, New York, 1964.
21. Krener A. The high order maximum principle and its application to singular control, SIAM J. Contr. Optim., 15, 1977, 256-293.